Viberect vs. Injection Study
Posted: Fri Sep 28, 2012 10:25 am
I cam across this study done at Tulane University. This is first study to my knowledge giving objective evidence of efficacy of the Viberect to provoke penile erection. It was not sponsored by the company.
An Objective Evaluation of Viberect® Vibratory Device in Comparison to Intracavernosal Vasoactive Injection for Penile Duplex Doppler Ultrasound Blood Flow Analysis
Suresh Sikka et. al. Tulane University
Background: Viberect® is a new FDA-cleared medical vibrator for inducing penile erection, a neurovascular event involving genital afferents.
Objective: We compare penile blood flow induced by Viberect® versus intracavernosal injection (ICI) using color duplex Doppler ultrasound (CDDU) technology.
Methods: Forty patients with erectile dysfunction consented to receive instructions and correctly use the vibrator prior to undergoing penile CDDU in our sexual dysfunction clinic. Viberect® stimulation was performed by the patient at 70-100 Hz for 6-10 minutes and CDDU performed as per standard protocol. After the penis was fully flaccid, an ICI (7-15 mcg prostaglandin-E1, PGE1) was administered and CDDU repeated.
Findings: Eighteen men (called “positive-responders” to Viberect®) showed similar systolic velocity measurements with 90% tumescence+70% rigidity erection response (2-tailed paired t-test value of 0.06). Ten patients showed “borderline” systolic velocity and 80% tumescence+30-40% rigidity with Viberect® compared to PGE1 (2-tailed paired t-test value of 0.002). Only four patients (called “non-responders”) showed no erection response with Viberect®, but good velocity and 90% tumescence + 60% rigidity with PGE1 (t-test value of 0.006). Eight patients did not complete Viberect® stimulation due to impending ejaculation. Thus, Viberect® induced blood flow response and erection similar to ICI in majority of patients undergoing CDDU evaluation. No complaints or adverse events were reported with Viberect®.
Conclusions: This study suggests that Viberect® that stimulate bulbocavernosus reflex, is a safe, convenient, well-tolerated modality for CDDU. Randomized prospective multicenter trials will be needed to further validate these results and the concept of stimulating bulbocavernosus reflex with Viberect® for ED diagnosis and treatment.
An Objective Evaluation of Viberect® Vibratory Device in Comparison to Intracavernosal Vasoactive Injection for Penile Duplex Doppler Ultrasound Blood Flow Analysis
Suresh Sikka et. al. Tulane University
Background: Viberect® is a new FDA-cleared medical vibrator for inducing penile erection, a neurovascular event involving genital afferents.
Objective: We compare penile blood flow induced by Viberect® versus intracavernosal injection (ICI) using color duplex Doppler ultrasound (CDDU) technology.
Methods: Forty patients with erectile dysfunction consented to receive instructions and correctly use the vibrator prior to undergoing penile CDDU in our sexual dysfunction clinic. Viberect® stimulation was performed by the patient at 70-100 Hz for 6-10 minutes and CDDU performed as per standard protocol. After the penis was fully flaccid, an ICI (7-15 mcg prostaglandin-E1, PGE1) was administered and CDDU repeated.
Findings: Eighteen men (called “positive-responders” to Viberect®) showed similar systolic velocity measurements with 90% tumescence+70% rigidity erection response (2-tailed paired t-test value of 0.06). Ten patients showed “borderline” systolic velocity and 80% tumescence+30-40% rigidity with Viberect® compared to PGE1 (2-tailed paired t-test value of 0.002). Only four patients (called “non-responders”) showed no erection response with Viberect®, but good velocity and 90% tumescence + 60% rigidity with PGE1 (t-test value of 0.006). Eight patients did not complete Viberect® stimulation due to impending ejaculation. Thus, Viberect® induced blood flow response and erection similar to ICI in majority of patients undergoing CDDU evaluation. No complaints or adverse events were reported with Viberect®.
Conclusions: This study suggests that Viberect® that stimulate bulbocavernosus reflex, is a safe, convenient, well-tolerated modality for CDDU. Randomized prospective multicenter trials will be needed to further validate these results and the concept of stimulating bulbocavernosus reflex with Viberect® for ED diagnosis and treatment.